A large biotech company has made a deal with a smaller firm to incorporate a new weapon into its arsenal against nonalcoholic steatohepatitis: machine learning.
Foster City, California-based Gilead Sciences said Tuesday that it had partnered with Insitro, based in nearby South San Francisco, to discover and develop new drugs for NASH. Insitro uses a platform called Human, or ISH, which combines genetics and functional genomics with machine learning to generate in vitro models to drive drug discovery and development. ISH will be used to provide information about disease progression, suggest drug candidate targets and predict responses to potential therapies, while Gilead will have rights to advance up to five targets and responsibility for chemistry and development efforts.
NASH is a form of fatty liver disease incidental to obesity and Type 2 diabetes. It is on the rise around the world and is expected by many analysts to represent a market that will explode in value over the next few years, but as yet has no approved treatments.
Under the deal between the two companies, Gilead will pay Insitro $15 million upfront, with near-term milestones of up to $35 million and another potential $200 million in preclinical, development, regulatory and commercial milestones. Insitro will also be eligible for low double-digit royalties, co-development and co-detail in the US, profit sharing in China and other milestones and royalties on sales outside the US.